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OBJECTIVE—To investigate early events leading to microvas-
cular cell loss in diabetic retinopathy.
RESEARCH DESIGN AND METHODS—FOXO1 was tested in
vivo by DNA binding activity and by nuclear translocation in
microvascular cells in retinal trypsin digests. In vivo studies were
undertaken in STZ-induced diabetic rats and Zucker diabetic fatty
rats using the tumor necrosis factor (TNF)-speciﬁc blocker, peg-
sunercept, or by inhibiting FOXO1 with RNAi. Microvascular cell
apoptosis, formation of pericyte ghosts, and acellular capillaries
were measured. Upstream and downstream effects of high-glucose–
induced FOXO1 were tested on rat microvascular endothelial cells
(RMECs) by small-interfering RNA (siRNA) in vitro.
RESULTS—DNA binding or nuclear translocation of FOXO1,
which was reduced by TNF inhibition, was elevated in type 1 and
type 2 diabetic retinas. Diabetes stimulated microvascular cell
apoptosis; pericyte ghost and acellular capillary development was
inhibited by FOXO1 siRNA. High glucose in vitro decreased FOXO1
phosphorylation and DNA binding activity and decreased Akt
phosphorylation in RMECs. High-glucose–stimulated FOXO1 DNA
binding activity was mediated through TNF- and formation of
reactive oxygen species (ROS), while inhibitors of TNF and ROS
and FOXO1 siRNA reduced high-glucose–enhanced RMEC apopto-
sis. The caspase-3/7 activity and capacity of high glucose to increase
mRNA levels of several genes that regulate RMEC activation and
apoptosis were knocked down by FOXO1 siRNA.
CONCLUSIONS—FOXO1 plays an important role in rat retinal
microvascular cell loss in type 1 and type 2 diabetic rats and can
be linked to the effect of high glucose on FOXO1 activation.
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iabetic retinopathy, the leading cause of vision
loss in occupational-age adults (1,2), is charac-
terized by early vascular lesions, including ap-
optosis of microvascular cells, formation of
pericyte ghosts, and the development of acellular capillar-
ies before the onset of clinical complications (3,4). The
formation of acellular capillaries eventually leads to hyp-
oxia, setting the stage for proliferative diabetic retinopa-
thy that ultimately results in impaired vision (5–8).
The loss of critical microvascular cells in the early stages
of this complication are not well understood. To investigate
this issue, we examined in type 1 and type 2 diabetic rats the
role of the transcription factor FOXO1, a forkhead transcrip-
tion factor that regulates cell death, inhibits cell cycle pro-
gression, and modulates differentiation in various cell types
(9–11). FOXO1 also has cell-speciﬁc effects modulating
genes that control gluconeogenesis (12), blood vessel
assembly during development (13), muscle wasting (14),
and inhibition of adipocyte differentiation (15).
We recently showed that diabetes-induced tumor necro-
sis factor (TNF)- plays an important role in microvascu-
lar cell loss (16). We demonstrate here for the ﬁrst time
that diabetes enhances FOXO1 DNA binding activity and
nuclear translocation in diabetic retinas through a process
that is mediated by TNF. Furthermore, inhibition of
FOXO1 by RNAi reduces microvascular cell apoptosis and
microvascular cell loss in diabetic retinas in vivo and by
high glucose in vitro. These results point to the previously
unrecognized role of FOXO1 in promoting apoptosis and
loss of microvascular cells in diabetic retinopathy.
RESEARCH DESIGN AND METHODS
Type 1 diabetic 8-week-old Sprague Dawley (SD) rats (Charles River
Laboratories, Wilmington, MA) were injected intraperitoneally with strepto-
zotocin (STZ) (55 mg/kg), and control animals received vehicle (0.05 mol/l
citrate buffer). Animals were subcutaneously injected with 1–5 units of NPH
insulin as needed to maintain serum glucose levels of 300 mg/dl. Type 2
diabetes was studied in Zucker diabetic fatty rats (fa/fa) (ZDF) and genetically
matched lean controls (fa/
) (Charles River Laboratories). Unless stated,
there were 6 animals per group, except for diabetic rats treated with vehicle
alone, which consisted of 12 animals per group. Serum glucose and weight
were monitored weekly. Glycosylated hemoglobin was measured (Helena
Laboratories, Beaumont, TX) when rats were killed. For short-term studies,
rats were killed 12 weeks after the onset of diabetes; for long-term studies,
they were hyperglycemic for 6 months and killed at age 33–34 weeks. All
measurements were performed by two blinded examiners.
Application of inhibitors. In short-term studies, FOXO1-speciﬁc small-
interfering RNA (siRNA) (CCA GCT ATA AAT GCA CAT TTA) or scrambled
siRNA (45 pmol in 5 l sterile water) was intravitreally injected in diabetic rats
that were hyperglycemic for 12 weeks (n  5); they were killed 10 days after
injection (17). There is no signiﬁcant homology between the sequence used for
FOXO1 siRNA and other forkhead box proteins. For long-term RNAi in STZ,
rats were hyperglycemic for 12 weeks and then given two intravitreal
injections of siRNA (45 pmol in 5 l sterile water) 6 weeks apart. The ZDF rats
received one intravitreal injection after 24 weeks of hyperglycemia and killed
10 days later.
In STZ-induced diabetic rats, pegsunercept (peg-TNFR1; 50 g) (Amgen,
Thousand Oaks, CA) was applied by intravitreal injections 6, 12, and 18 weeks
after becoming hyperglycemic. Pegsunercept was given to ZDF rats 12 and 18
weeks after becoming hyperglycemic. Pegsunercept is a speciﬁc TNF inhibitor
consisting of a pegylated recombinant soluble TNF receptor-1 (18). For both
groups controls received vehicle (sterile PBS) alone.
Apoptosis, acellular capillaries, and pericyte ghosts. Retinal trypsin
digests (RTDs) were assesed by a ﬂuorometic terminal dUTP nick-end
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diabetes.diabetesjournals.org DIABETES, VOL. 58, APRIL 2009 917labeling (TUNEL) assay (Promega, San Luis Obispo, CA) and by immunohis-
tochemistry using an antibody speciﬁc for activated caspase-3 (Cell Signaling
Technology, Danvers, MA). RTDs were permeablized (0.5% Triton X-100) and
incubated with blocking agent (Chemicon, Temecula, CA), primary or
matched control antibody, and biotinylated secondary antibody and ﬂuores-
cein avidin (Vector Laboratories, Burlingame, CA). Mounting media contained
nuclear stain 4,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). The
entire specimen was surveyed for TUNEL-positive or caspase-3–positive cells
by ﬂuorescence microscopy (original magniﬁcation 400). RTDs were stained
with periodic acid Schiff (PAS)-hematoxylin (6), and 13–15 ﬁelds in the
midretina were examined as described (16).
FOXO1 nuclear translocation. FOXO1 nuclear translocation was detected
by confocal laser–scanning microscopy (Axiovert-100M; Carl Zeiss). Primary
antibody to FOXO1 (Santa Cruz Biotech, Santa Cruz, CA) was detected by a
Cy5-tagged secondary antibody and nuclei with propidium iodide. The entire
RTD was scanned for nuclear FOXO1-positive microvascular cells examining
single and merged images. Matched control IgG was negative, demonstrating
speciﬁcity (data not shown).
FOXO1 DNA binding. Nuclear protein from whole retinas of rats that were
hyperglycemic for 12 weeks and matched normoglycemic controls was
measured using a kit from Pierce Biotechnology (Rockford, IL). FOXO1 DNA
binding activity was examined in nuclear extracts with a transcription factor
DNA binding kit (Active Motif, Carlsbad, CA).
Real-time PCR. Retinas of STZ-induced diabetic rats, hyperglycemic for 12
weeks with or without pegsunercept for the last 8 weeks, and age-matched
control rats (n  6) were snap frozen (16). Total RNA (RNAeasy Mini Kit;
Qiagen, Valencia, CA) was isolated and FOXO1 mRNA levels quantiﬁed by
real-time PCR using TaqMan primers and probes (Applied Biosystems, Foster
City, CA).
FOXO1 DNA binding and caspase-3/7 activity in vitro. Rat microvascular
endothelial cells (RMECs) were isolated, characterized, and cultured as
described (17,19) and examined at passages 3–8. Cells were cultured in
DMEM plus 10% fetal bovine serum (FBS) and changed to 0.5% FBS at least
24 h before the start of experiments. In some experiments, RMECs were
preincubated with 10 mmol/l N-acetyl-L-cysteine (NAC) (Sigma-Aldrich) for
2 h followed by incubation with media supplemented with glucose (25 mmol/l)
and NAC as indicated. Nuclear protein was isolated and assayed for FOXO1
DNA binding activity (Active Motif). Cytoplasmic proteins were extracted
using a kit from Pierce Biotechnology, and caspase-3/7 activity was measured
with a caspase-glo 3/7 kit from Promega (Mannheim, Germany).
FOXO1 and AKT phosphorylation. RMECs were cultured in 96-well plates
in DMEM plus 0.25% FBS, transfected with or without rat FOXO1-speciﬁc
siRNA (5 nmol/l in HiPerfect transfection reagent), or scrambled siRNA
(Qiagen) and then incubated in high-glucose media (25 mmol/l) for 5 days.
Some wells were incubated with Akt inhibitor (Calbiochem, Gibbstown, NJ).
FOXO1 protein, phosphorylated FOXO1, total AKT protein, and phosphory-
lated AKT levels were determined by using an in situ detection kit from Active
Motif. Cells were incubated in high glucose; ﬁxed with 4% paraformaldehyde;
permeablized; and incubated with blocking solution followed by primary
antibodies to FOXO1, phosphorylated FOXO1, AKT, phosphorylated AKT, or
matched control antibody followed by horseradish peroxidase–conjugated
secondary antibody. After addition of colorimetric substrate, optical density
was measured at 450 nm and corrected for cell number by crystal violet
staining and optical density at 695 nm.
Apoptosis in vitro. RMECs were cultured in DMEM plus 0.25% FBS and
transfected with or without rat FOXO1-speciﬁc siRNA (5 nmol/l in HiPerfect
transfection reagent) or scrambled siRNA (Qiagen) and then incubated with
TNF- (20 ng/ml, 6 h) or media supplemented with glucose or mannitol (25
mmol/l) for 5 days. Some RMECs were incubated with 10 mmol/l of NAC
(Sigma-Aldrich) or the caspase-3/7–speciﬁc inhibitor (Z-DEVD-FMK; R&D
Systems) plus high glucose (25 mmol/l) for 5 days. Apoptosis was measured by
enzyme-linked immunosorbent assay (ELISA) measuring cytoplasmic histone-
associated DNA (Roche Diagnostics), as we have described (20).
Focused microarray analysis and real-time PCR validation. Total RNA
was isolated (RNAeasy; Qiagen) from primary RMECs transfected with
FOXO1 or scrambled siRNA, as described above, and then incubated in
standard media or media supplemented with glucose or mannitol (25 mmol/l)
for 5 days. Focused microarrays (Oligo GEArray; SuperArray, Bethesda, MD)
were carried out as we have described (21), and the spot intensity from
chemiluminescent images were analyzed using the GeaSuite array analysis
(SuperArray). Spot intensities were normalized with ribosomal protein (L32).
A value was considered to be modulated if both the mean and the median
intensity level in the experimental group was 1.7-fold higher or lower than that
of the mean of the corresponding control. Selected genes were conﬁrmed by
real-time PCR (Applied Biosystems). Assays were carried out three times to
provide means 	 SE.
Statistical analysis. For all in vitro assays, experiments were carried out
three times to provide means 	 SE. Statistical signiﬁcance was determined by
one-way ANOVA with Tukey’s post hoc test for comparisons between multiple
groups at the P 
 0.05 level.
RESULTS
Type 1 diabetic rats had reduced weight and higher gly-
cosylated hemoglobin levels compared with normoglyce-
mic rats, while type 2 diabetic rats weighed more and had
higher glycosylated hemoglobin levels compared with
normoglycemic littermates (data not shown). Treatment
with siRNA or pegsunercept had no effect on these param-
eters (data not shown).
Diabetes increased FOXO1 nuclear translocation in
microvascular cells in vivo and mediated by TNF-.
FOXO1 nuclear translocation was examined in retinal trypsin
digests (RTDs) containing isolated microvascular cells by
laser-scanning confocal microscopy. It reﬂects the activation
status since FOXO1 is rapidly transported to the nuclear
compartment in the activated state and upon deactivation is
quickly transported out of the nucleus (10,11). Confocal
microscopy avoids some of the pitfalls of standard immuno-
ﬂuorescence since the images are taken at a focal plane that
bisects the nuclear compartment. An example of a microvas-
cular endothelial cell and pericyte with FOXO1 nuclear
translocation is evident in Fig. 1. Microvascular cells that
were positive for FOXO1 nuclear translocation typically
exhibited increased cytoplasmic expression consistent with
an overall increase in expression. Conversely, cells without
FOXO1 nuclear translocation typically exhibited only faint
FOXO1 immunoﬂuorescence in the cytoplasm, indicating a
low basal level of expression as indicated (Fig. 1). Additional
images demonstrating the FOXO1 nuclear staining in micro-
vascular cells are shown in the online appendix (online
appendix Figs. 1–3 [available at http://dx.doi.org/10.2337/
db08-0537]). The number of retinal microvascular cells with
FOXO1 in the nuclear compartment increased ﬁvefold in
type 1 diabetic rats that had been hyperglycemic for 6
months (Fig. 1C) and almost fourfold in type 2 diabetic rats
(Fig. 1D) compared with normoglycemic rats. The midretinal
area was further examined and cells that were positive for
FOXO1 nuclear staining based upon the confocal micro-
scopic images were characterized as endothelial cells, peri-
cytes, or undetermined based upon the shape and location of
nuclei (as described in 16). FOXO1 nuclear translocation–
positive microvascular cells were primarily endothelial cells
with an endothelial cell to pericyte ratio of 2:1 (Table 1).
To investigate a potential mechanism for diabetes-en-
hanced FOXO1 nuclear translocation, rats were treated
with pegsunercept. TNF inhibition for 12 weeks reduced
cells with FOXO1-positive nuclei by 76% in type 1 diabetic
(Fig. 1C) and 65% in type 2 diabetic (Fig. 1D) rats. Diabetes
increased FOXO1 mRNA more than twofold (Fig. 1E), and
pegsunercept reduced it by 64% (P 
 0.05) (Fig. 1E).
Similarly type 1 diabetes increased FOXO1 DNA binding
activity more than twofold (Fig. 1F), and TNF inhibition
reduced this increase by 74% (P 
 0.05) in the STZ-induced
diabetic rats (Fig. 1F). Diabetes also signiﬁcantly in-
creased FOXO1 DNA binding in retinas of type 2 diabetic
rats (Fig. 1G).
FOXO1 inhibition by RNAi reduces microvascular
cell apoptosis in diabetic retinas in vivo. A single
intravitreal injection of FOXO1 siRNA 10 days before the
rats were killed blocked virtually all of the diabetes-
increased FOXO1 mRNA, demonstrating efﬁcacy of RNAi
in vivo (P 
 0.05) (Fig. 2A). Scrambled siRNA had no effect
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 0.05). In long-term experiments, FOXO1 siRNA
applied 6 and 12 weeks before the type 1 diabetic rats were
killed reduced diabetes-enhanced FOXO1 nuclear translo-
cation in microvascular cells by 86% (P 
 0.05) (Fig. 2B).
Scrambled siRNA had no effect (P  0.05).
The role of FOXO1 in microvascular apoptosis and the
cumulative effect of apoptosis as reﬂected by pericyte
ghost formation and the development of acellular capillar-
ies was examined (23). Type 1 diabetes increased the
number of TUNEL-positive cells sevenfold, which was
reduced 75% by FOXO1 siRNA (P 
 0.05) in the STZ-
induced diabetic rats (Fig. 2C). Diabetes induced a sixfold
increase in pericyte ghost formation, which was reduced
TABLE 1
Distribution of cells with FOXO1 nuclear translocation in RTDs
Distribution of cells with FOXO1
nuclear translocation (%)
Endothelial cells 63
Pericytes 28
Undetermined 9
Data are percent. Midretinal areas in RTDs were scored, and cells
with FOXO1 nuclear localization were assessed in confocal laser–
scanning microscopic images. Cells were categorized as endothelial
cells, pericytes, or undetermined based on the shape and location of
nuclei as described in RESEARCH DESIGN AND METHODS.
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FIG. 1. Diabetes-induced increase in FOXO1 mRNA, DNA binding, and nuclear translocation in the retina is partly dependent on TNF-. A: RTDs from
diabetic rats that were hyperglycemic for 6 months along with age-matched normoglycemic rats were incubated with antibody to FOXO1 and
Cy5-tagged secondary antibody (upper left), counterstained with propidium iodide (upper right), and examined by confocal laser-scanning microscopy.
Merged FOXO1/propidium iodide (lower right) and phase-contrast (lower left) images are shown. Arrow points to nuclear FOXO1-positive endothelial
cells. Incubation with control antibody revealed no staining (data not shown). Original magniﬁcation 400. B: RTDs from diabetic rats that were
hyperglycemic for 6 months along with age-matched normoglycemic rats were incubated with antibody to FOXO1 and Cy5-tagged secondary antibody
(upper left), counterstained with propidium iodide (upper right), and examined by confocal laser-scanning microscopy. Merged FOXO1/propidium
iodide (lower right) and phase-contrast (lower left) images are shown. Arrow points to nuclear FOXO1-positive pericytes. Incubation with control
antibody revealed no staining (data not shown). Original magniﬁcation 400. C: The mean number of cells with clearly identiﬁed FOXO1 nuclear
translocation was determined in STZ-induced diabetic rats (DM), STZ-induced diabetic rats treated with pegsunercept (DM  Peg), and age-matched
normoglycemic control (C) rats. Each value is the mean  SE (n  5/group). D: The mean number of cells with clearly identiﬁed FOXO1 nuclear
translocation was determined in ZDF rats treated with vehicle alone (D), ZDF rats treated with pegsunercept (D  Peg), and age-matched
normoglycemic control (C) rats. Each value is the mean  SE (n  6/group). E: RNA was isolated from whole retinas and mRNA levels of FOXO1
determined by real-time PCR from STZ-induced diabetic rats (DM) that had been hyperglycemic for 12 weeks and treated with vehicle alone, diabetic
rats treated with pegsunercept (DM  Peg) for 8 weeks before euthanasia, and age-matched normoglycemic control (C) rats. The data presented is
mean fold change  SE (n  6/group). F: Nuclear proteins were isolated from whole retina of STZ-induced diabetic rats (DM) with hyperglycemia of
12 weeks duration treated with vehicle alone, STZ-induced diabetic rats treated with pegsunercept (DM  Peg) for 8 weeks before euthanasia, and
age-matched normoglycemic control (C) rats. Nuclear proteins were assayed for FOXO1 DNA binding activity using a transcription factor ELISA. Each
value is the mean  SE (n  6/group). G: Nuclear proteins were isolated from whole retinas of ZDF rats (DM) with 12 weeks hyperglycemia and
age-matched normoglycemic control (C) rats. Nuclear proteins were assayed for FOXO1 DNA binding activity. Each value is the mean  SE (n 
6/group). *Signiﬁcantly higher in the diabetic than normoglycemic group (P < 0.05). **Signiﬁcantly less in pegsunercept than vehicle-treated rats (P <
0.05). (Please see http://dx.doi.org/10.2337/db08-0537 for a high-quality digital representation of this ﬁgure.)
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 0.05) (Fig. 2D and supple-
mental Fig. 6). Similarly, type 1 diabetes increased acellu-
lar capillary formation by twofold (P 
 0.05), and FOXO1
siRNA reduced this increase by 60% (P 
 0.05) in the
STZ-induced diabetic rats (Fig. 2E). For all three parame-
ters, scrambled siRNA had no effect (P  0.05).
FOXO1 RNAi reduces microvascular cell apoptosis in
the retina of type 2 diabetic rats. The impact of
silencing FOXO1 on microvascular cell apoptosis was
assessed in retinal trypsin digests in type 2 diabetic
animals. An 8-fold increase in retinal microvascular endo-
thelial cells expressing activated caspase-3 caused by
diabetes was reduced 74% by FOXO1 siRNA (P 
 0.05)
(Fig. 3A), and a 10-fold increase in pericytes was reduced
by 80% (P 
 0.05) (Fig. 3A). FOXO1 siRNA also reduced
the ﬁvefold increase in diabetes-enhanced TUNEL-positive
endothelial cells by 79% and the ﬁvefold increase in
TUNEL-positive pericytes by 71% (P 
 0.05) (Fig. 3B).
Scrambled siRNA had no effect (P  0.05). Representative
images of caspase-3 and TUNEL-positive retinal microvas-
cular endothelial cells are shown in supplemental Figs. 4
and 5. As an additional control, immunohistochemistry
experiments were carried out with antibody to CD18,
demonstrating that there were very few immune cells
trapped within the microvasculature and none of these
were apoptotic when immunohistochemistry with CD18
was combined with the TUNEL assay (data not shown).
High glucose stimulates FOXO1 DNA binding and
modulates FOXO1 phosphorylation in RMECs in
vitro, and high-glucose–stimulated apoptosis is re-
duced by FOXO1 silencing. Incubation of RMECs with
high glucose induced a dose-dependent increase in FOXO1
DNA binding that was increased 2.3-fold in 25 mmol/l
glucose compared with standard glucose (5 mmol/l), while
D-mannitol (25 mmol/l) had no effect (P  0.05) (Fig. 4A),
demonstrating that the effect is not due to osmotic shock.
To establish whether high glucose altered FOXO1 protein
and its phosphorylation status, assays were performed in
cellulo. High glucose signiﬁcantly increased total FOXO1
protein level twofold, while simultaneously reducing phos-
phorylated FOXO1 by 37% (P 
 0.05) (Fig. 4B), consistent
with FOXO1 activation. High glucose increased FOXO1
mRNA level 1.7-fold (P 
 0.05), and transfection with
FOXO1 siRNA reduced it by 61% (P 
 0.05) (Fig. 4C).
FOXO1 siRNA also reduced total FOXO1 protein levels in
high-glucose–stimulated RMECs by 57% compared with
scrambled siRNA (P 
 0.05) (Fig. 4D), consistent with
reports that siRNA achieves knockdown for 5 days in
dividing cells and 3 weeks in nondividing cells (24). High
glucose induced a 2.3-fold increase in RMEC apoptosis,
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FIG. 2. FOXO1 siRNA effectively reduces FOXO1 mRNA level and nuclear translocation in vivo and reduces diabetes induced microvascular cell
loss in STZ-induced diabetic rats. A: RNA was isolated from whole retinas and mRNA levels of FOXO1 determined by real-time PCR from
STZ-induced diabetic rats (DM) that had been hyperglycemic for 12 weeks, matched diabetic rats treated with FOXO1 siRNA (DM  FOXO1
siRNA) or scrambled siRNA (DM  scrambled siRNA) for 10 days before euthanasia, and age-matched normoglycemic control (C) rats. Data
represent mean relative fold change compared with control  SE (n  5/group). B: The mean number of cells with clearly identiﬁed FOXO1
nuclear translocation was determined in STZ-induced diabetic rats (DM) that had been hyperglycemic for 6 months, matched diabetic rats
treated with FOXO1 siRNA (DM  FOXO1 siRNA), scrambled siRNA (DM  scrambled siRNA) applied by two intravitreal injections at 12 and
6 weeks before euthanasia, and age-matched normoglycemic control (C) rats (n  5/group). Data represent the mean  SE. C: The mean number
of TUNEL-positive microvascular cells was determined in STZ-induced diabetic rats (DM) that had been diabetic for 6 months, matched diabetic
rats treated with FOXO1 siRNA (DM  FOXO1 siRNA), or scrambled siRNA (DM  scrambled siRNA) and age-matched normoglycemic control
(C) rats, by intravitreal injections at 12 and 6 weeks before euthanasia (n  5). D: The mean number of pericyte ghosts was determined in
PAS-stained RTDs from groups described above in (C). E: The mean number of acellular capillaries was determined in PAS-stained RTDs from
groups described above in (C). Data represent the means  SE. *Signiﬁcantly higher in diabetic than normoglycemic rats (P < 0.05).
**Signiﬁcantly less with FOXO1 siRNA compared with scrambled siRNA (P < 0.05).
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in high-glucose–stimulated apoptosis (P 
 0.05) (Fig. 4E).
High glucose reduces phosphorylated AKT and FOXO1
levels in RMECs in vitro. Incubation in high glucose
caused a 32% reduction (P 
 0.05) in phosphorylated Akt
without affecting AKT protein levels (Fig. 5A). The func-
tional importance of Akt in FOXO1 was assessed by using
an Akt inhibitor, which further reduced high-glucose–
diminished FOXO1 phosphorylation by 52% compared
with high glucose alone (P 
 0.05) (Fig. 5B). The Akt
inhibitor did not affect FOXO1 protein levels (Fig. 5C).
TNF inhibition reduces high-glucose–induced FOXO1
DNA binding activity and high-glucose–induced FOXO1
DNA binding in a reactive oxygen species–dependent
manner. Both high glucose and TNF stimulate FOXO1
DNA binding activity (Fig. 5D and E). Moreover, TNF, in
part, mediates high-glucose–stimulated FOXO1 DNA bind-
ing since pegsunercept reduces it by 42% (P 
 0.05) (Fig.
5D). FOXO1 siRNA also reduced FOXO1 mRNA levels by
65% in RMECs stimulated with TNF- (P 
 0.05) com-
pared with scrambled siRNA (Fig. 5E) and reduced TNF-
–stimulated apoptosis of RMECs by 64% (P 
 0.05) (Fig.
5F). To identify the potential upstream and downstream
mechanism, in vitro experiments with RMECs revealed
that high-glucose–induced FOXO1 DNA binding returned
to baseline levels when reactive oxygen species (ROS)
inhibitor was used compared with high glucose alone (Fig.
5G). Under similar conditions, apoptosis was reduced by
61% when ROS formation was inhibited (Fig. 5H). High
glucose also led to greater caspase-3/7 activation, and
FOXO1 siRNA reduced high-glucose–induced caspase-3/7
activation by 50% (P 
 0.05) (Fig. 5I). In addition, when
a caspase-3/7 inhibitor was used, high-glucose–stimulated
apoptosis was reduced by 50% (P 
 0.05) (Fig. 5J). Thus,
high glucose appears to induce RMECs apoptosis through
a mechanism that involves reduced FOXO1 phosphoryla-
tion and increased FOXO1 mRNA, protein, and DNA
binding activity. Furthermore, high-glucose–induced
FOXO1 DNA binding activity or apoptosis is mediated by
formation of ROS and TNF.
FOXO1 regulates high-glucose–induced gene expres-
sion. To identify potential mechanisms through which
FOXO1 may mediate the effects of hyperglycemia, mRNA
proﬁling with focused microarrays was undertaken. The
mean and median values of three microarrays per assay
conditions are shown compared with the mean on the
corresponding control with a threshold set at a minimum
1.7-fold increase or 0.58-fold decrease. The genes were
divided into three functional groups regulating endothelial
cell activation, endothelial cell apoptosis, and angiogene-
sis (Table 2). High glucose enhanced the mRNA levels of
10 of 14 genes (CCL2, CCL5, F3, ICAM1, IL6, PLAT, TFPI,
TFPI2, THBD, and VCAM1) that modulate endothelial cell
activation by 2.0- to 3.5-fold. FOXO1 siRNA reduced
mRNA levels of all 14 genes belonging to this group by
0.12- to 0.58-fold. All eight genes (BCL2, CASP3, CASP6,
TNF-, TNFRSF11B, BCL2A1, BIRC3, and BIRC4) tested
that are involved in apoptosis were increased by high
glucose from 1.7- to 2.9-fold. FOXO1 siRNA reduced
mRNA levels of ﬁve (BCL2, CASP3, CASP6, TNF-, and
TNFRSF11B) of these from 0.34- to 0.45-fold.
The majority of genes involved in angiogenesis were not
modulated by high glucose but were by FOXO1 (Table 2).
High glucose stimulated an increase in mRNA levels of 4
(ITGB1, ANGPT1, FLT4, and VEGF) of 10 of these genes
from 2.6- to 4.9-fold. FOXO1 siRNA reduced mRNA of
these four as well as others (ITGA5, ITGAV-M, ITGB3,
KDR, and TEK) by 0.29- to 0.54-fold. Genes from each
functional category were selected and results with mi-
croarrays were conﬁrmed by real-time PCR (Fig. 6). For
CASP-3, ICAM1, VEGF, and TNF-, stimulation with high
glucose induced a minimum 1.7-fold increase and inhibi-
tion by FOXO1-induced a 0.58-fold decrease whether as-
sayed by microarray or by real-time PCR.
DISCUSSION
We report for the ﬁrst time that diabetes increases FOXO1
mRNA levels and DNA binding activity in the retina. In
addition, both type 1 and type 2 diabetic models exhibited
increased FOXO1 nuclear translocation in retinal micro-
vascular cells. These increases occurred in a time frame
when increased inﬂammation, caspase-3–positive cells,
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FIG. 3. FOXO1 siRNA reduces retinal microvascular endothelial cell
and pericyte apoptosis in ZDF rats. A: The mean number of cleaved
caspase-3–positive endothelial cells and pericytes were determined in
RTDs from ZDF rats that were hyperglycemic for 6 months (DM, f),
ZDF rats treated with FOXO1 siRNA (DM  FOXO1 siRNA, p), ZDF
rats treated with scrambled siRNA (DM  scrambled siRNA, `), and
from age-matched normoglycemic control rats (C, u), applied by an
intravitreal injection 10 days before euthanasia. Pericytes and endo-
thelial cells were determined by comparison of a bright ﬁeld image of
the same ﬁeld PAS stained. B: The mean number of TUNEL-positive
endothelial cells and pericytes were measured in RTDs from ZDF rats
that were hyperglycemic for 6 months (DM), ZDF rats treated with
FOXO1 siRNA (DM  FOXO1 siRNA), ZDF rats treated with scrambled
siRNA (DM  scrambled siRNA), and from age-matched normoglycemic
control (C) rats, as described in B. Each value represents the mean
number per RTD  SE. (n  6/group). *Signiﬁcantly higher in diabetic
than normoglycemic rats (P < 0.05). **Signiﬁcantly less with FOXO1
siRNA compared with scrambled siRNA (P < 0.05).
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over, TNF-mediated diabetes enhanced FOXO1 mRNA
levels, DNA binding, and nuclear translocation. Thus, we
propose that diabetes increases TNF-, which enhances
FOXO1 mRNA levels, nuclear translocation, and DNA
binding in retinas of type 1 and type 2 diabetic rats.
The functional signiﬁcance of FOXO1 was tested by
RNAi. Intravitreal injection of FOXO1 siRNA signiﬁcantly
reduced FOXO1 mRNA levels and FOXO1 nuclear trans-
location, while control-scrambled siRNA had no effect.
The effect of FOXO1 knockdown by siRNA was evident 6
weeks after the second injection, indicating that silencing
is effective for at least 6 weeks. In type 1 diabetic rats,
FOXO1 siRNA signiﬁcantly decreased microvascular cell
apoptosis, the formation of pericyte ghosts, and the devel-
opment of acellular capillaries. Similar results were found
in type 2 diabetic rats. FOXO1 siRNA signiﬁcantly reduced
cleaved caspase-3– and TUNEL-positive pericytes and
endothelial cells. This represents the ﬁrst demonstration
that FOXO1 plays a critical role in diabetes-induced apop-
tosis and retinal microvascular cell loss.
In retinal microvascular endothelial cells, high glucose
was shown to increase FOXO1 mRNA and protein levels.
In addition, high glucose reduced FOXO1 phosphorylation,
consistent with increased DNA binding activity, since
FOXO1 is deactivated by phosphorylation. High glucose
did not affect total Akt levels but did signiﬁcantly decrease
the active phosphorylated isoforms of Akt. When Akt was
inhibited there was a further decrease in FOXO1 phos-
phorylation, indicating that high glucose levels could mod-
ulate FOXO1 through its effect on Akt. In addition,
hypoinsulinemia or insulin resistance associated with dia-
betes could potentially contribute to decreased phosphor-
ylation of Akt in vivo and contribute to enhanced FOXO1
activity (25).
As discussed above, TNF-mediated diabetes enhanced
FOXO1 activation both in vitro and in vivo. Further-
more, TNF stimulated apoptosis that was reduced by
FOXO1 siRNA. Similarly, ROS inhibitor reduced high-
glucose–stimulated FOXO1 DNA binding activity and
high-glucose–induced apoptosis. Also, high-glucose–
stimulated apoptosis was inhibited by FOXO1 siRNA.
Thus, several pathways by which high glucose increased
FOXO1 were tested. In each case, the factor was shown
to mediate high-glucose–stimulated apoptosis of retinal
endothelial cells. The results obtained in vitro and in
vivo are strikingly similar and indicate that hyperglyce-
mia per se could stimulate apoptosis of microvascular
cells through a mechanism not involving other cell
types, although it cannot be ruled out that other cell
types or leukostasis in the retina may play an important
role in the apoptotic process (26,27).
In vitro mRNA proﬁling suggests that FOXO1 mediates
high-glucose–induced mRNA expression of genes that
modulate endothelial cell activation and apoptosis and the
basal expression of genes that affect angiogenesis, which
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FIG. 4. High glucose enhances FOXO1 DNA binding and decreases FOXO1 phosphorylation in the retinal microvascular endothelial cells in vitro,
and FOXO1 siRNA reduces high glucose increased FOXO1 mRNA, protein, and apoptosis. A: RMECs were incubated in standard culture media (5
mmol/l glucose), media with high glucose (15–35 mmol/l), or media with 25 mmol/l mannitol for 5 days. Extracted nuclear proteins were tested
for FOXO1 DNA binding activity by transcription factor ELISA. B: RMECs were incubated with standard media (C) or high-glucose media, 25
mmol/l (HG). Following treatment, total and phosphorylated FOXO1 levels were measured in cellulo. C: RMECs were transfected with FOXO1
siRNA or scrambled siRNA in vitro for 24 h. After transfection cells were incubated in standard media (5 mmol/l) or media with high glucose (25
mmol/l) for 5 days. mRNA levels of FOXO1 were determined by real-time PCR and normalized by the level of 18S rRNA in the same sample. D:
cells treated as in C were assessed for FOXO1 protein in cellulo.E : Cells described in C were assayed for apoptosis by ELISA measuring
cytoplasmic histone-associated DNA. Each value represents the mean  SE obtained from three independent experiments.
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ﬁnding was that FOXO1 siRNA reduced mRNA levels of
several genes that regulate proinﬂammatory and proco-
agulant responses. Thus, FOXO1 could induce expression
of genes that participate in the very early events that affect
diabetic retinal microvascular endothelial cells, many of
which are known to be increased by diabetes (28–30). This
is signiﬁcant since it has not previously been recognized
that FOXO1 could modulate proinﬂammatory gene expres-
sion. However, it is consistent with activation of FOXO1
during the early inﬂammatory phase of diabetic retinopa-
thy. In addition, FOXO1 siRNA modulated a high percent-
age of proapoptotic genes, consistent with its known
proapoptotic function (20). This is supported by data
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FIG. 5. High glucose modulates AKT and FOXO1 and high glucose induced apoptosis is mediated by TNF, ROS, FOXO1, and caspase-3 in retinal
microvascular endothelial cells. A: RMECs were incubated with standard media (C) or high glucose (HG) for 5 days as described above and
assayed for AKT protein and phosphorylated AKT in cellulo. B: RMECs were incubated with standard media (C; 5 mmol/l), high glucose (HG; 25
mmol/l), or high glucose with AKT inhibitor (HG  AKT inhibitor) for 5 days and assayed for phosphorylated FOXO1 protein. C: RMECs were
incubated with standard media (C; 5 mmol/l), high glucose (HG; 25 mmol/l), or high glucose with AKT inhibitor (HG  AKT inhibitor) for 5 days
and assayed for total FOXO1 protein. D: RMECs were incubated with standard media (C), high-glucose media, 25 mmol/l (HG), and high-glucose
media plus 10 g/ml pegsunercept (HG  Peg) for 5 days. Following treatment, extracted nuclear proteins were tested for FOXO1 DNA binding
by transcription factor ELISA. E: RMECs were transfected with FOXO1 siRNA or scrambled siRNA as described in A and incubated with or
without TNF- (20 ng/ml) for 6 h. mRNA levels of FOXO1 were determined by real-time PCR and normalized by the level of 18S rRNA in the same
sample. F: RMECs were transfected with FOXO1 siRNA or scrambled siRNA followed by stimulation with or without TNF- (20 ng/ml) for 6 h.
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experiments  SE. *Signiﬁcantly different in high glucose compared with standard glucose (P < 0.05). **Signiﬁcantly different in treated high
glucose compared with untreated high glucose.
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stimulated caspase-3 activity and apoptosis in microvas-
cular endothelial cells in vitro. Furthermore, inhibition of
caspase-3 blocked high-glucose–stimulated apoptosis,
consistent with FOXO1-regulated caspase-3 mRNA levels
and caspase-3 activity. Last, mRNA expression of genes
associated with angiogenesis were also enhanced by high
glucose and/or reduced by FOXO1 siRNA. This is consis-
tent with a report that FOXO1 overexpression induces
genes that regulate angiogenesis and vascular remodeling
(31). Thus, high glucose and FOXO1 had a dramatic effect
on genes that regulate a relatively diverse array of genes
that modulate endothelial cell behavior, several of which
are thought to contribute to diabetic retinopathy (30).
FOXO1 can affect gene expression without directly bind-
ing to DNA (32). For example, FOXO1 can regulate tran-
scription by enhancing the activity of CCAAT/enhancer
binding protein  or by modulating the DNA binding and
transcriptional activity of PAX3 (33,34).
Few studies have examined the role of transcription
factors in early diabetic retinopathy, and a limitation of
our studies is that it is unknown if these ﬁndings pertain to
humans with diabetes. Findings from the short-term appli-
cation of FOXO1 RNAi point to the possibility of using
long-term inhibition of FOXO1 by shRNA in diabetic
retinopathy. Moreover, FOXO1 may potentially play an
important role in other diabetes complications, where
locally enhanced inﬂammation and apoptosis are associ-
ated with pathologic changes. In summary, studies pre-
sented here demonstrate a mechanistic link between
diabetes, enhanced TNF- levels in the retina, increased
FOXO1nucleartranslocation,andmicrovascularcellapop-
tosis. This provides a basis for understanding how chronic
low-grade inﬂammation may play a role in early diabetic
retinopathy.
TABLE 2
Genes regulated by high glucose or high glucose plus FOXO1
siRNA in RMECs
Gene
Unique
identiﬁcation
High glucose
High glucose
plus FOXO1
siRNA
Mean Median Mean Median
Endothelial cell
inﬂammation/
activation
CCL2 Rn.4772 2.2 1.7 0.4 0.3
CCL5 Rn.8019 2.1 2.1 0.1 0.1
CXCL1 Rn.10907 2.8 2.5 0.3 0.2
ICAM1 Rn0.12 2.3 2.0 0.4 0.4
IL6 Rn.9873 2.4 2.0 0.3 0.3
IL7 Rn.10793 2.3 1.7 0.3 0.2
VCAM1 Rn.11267 2.8 2.0 0.3 0.3
ANXA5 Rn.3318 1.6 1.6 0.6 0.6
CCL20 Rn.10722 2.4 1.6 0.3 0.3
CPB2 Rn.12572 1.9 1.2 0.5 0.6
CSF2 Rn.44285 1.4 1.2 0.3 0.2
ICAM2 Rn.138519 3.0 1.1 0.2 0.2
INOS Rn.10400 1.9 1.3 0.4 0.5
SEL-E Rn.10359 1.7 1.0 0.4 0.3
SEL-L Rn.10461 1.8 1.1 0.3 0.3
SEL-P Rn.10012 2.0 1.2 0.3 0.3
TGFB1 Rn.40136 2.6 1.5 0.3 0.2
TGFB2 Rn.24539 2.3 1.5 0.3 0.2
VWF Rn.35561 1.7 1.1 0.4 0.3
IL11 Rn.47218 1.4 0.7 0.3 0.5
IL15 Rn.2490 2.0 1.1 0.2 0.2
IL3 Rn.10652 1.0 0.5 0.3 0.6
Endothelial cell
apoptosis
BAX Rn.10668 2.5 2.0 0.5 0.5
BCL2 Rn.9996 2.5 2.1 0.4 0.4
CASP3 Rn.10562 2.9 2.4 0.5 0.5
CASP6 Rn.88160 4.1 4.2 0.3 0.3
CASP8 Rn.54474 2.0 1.9 0.5 0.5
TNFRSF11B Rn.9792 1.7 1.7 0.3 0.4
TNFRSF10B Rn.105558 2.6 1.5 0.3 0.4
BCL2A1 Rn.19770 1.7 1.7 0.7 0.7
BIRC3 Rn.64578 1.8 1.7 0.7 0.7
BIRC4 Rn.91239 2.8 1.7 0.7 0.8
Angiogenesis
ITGB1 Rn.25733 2.6 2.0 0.3 0.3
ANGPT1 Rn.120272 4.9 4.6 0.4 0.4
FLT4 Rn.81043 3.5 2.7 0.2 0.2
VEGFA Rn.1923 3.0 2.8 0.4 0.3
ITGA5 Rn.100796 2.8 1.1 0.4 0.4
ITGB3 Rn.17129 2.4 1.4 0.3 0.3
KDR Rn.88869 1.9 1.1 0.4 0.4
MMP2 Rn.6422 2.5 1.6 0.4 0.4
MMP9 Rn.10209 2.1 1.3 0.3 0.4
TEK Rn.9159 3.9 1.6 0.3 0.3
COL18A1 Rn.12030 2.2 1.3 0.5 0.5
PLG Rn.20178 1.7 1.1 0.5 0.6
Data are mean and median of three independent arrays for each time
point. Boldface indicates that both the mean and median of the
experimental group was 1.7- or 0.58-fold of the corresponding
control (high glucose versus low glucose; high glucose plus FOXO1
siRNA versus high glucose plus scrambled siRNA). RMECs were
incubated with or without high glucose (25 mmol/l) for 5 days. Some
cells were transfected with FOXO1 siRNA or scrambled siRNA for
24 h prior to incubation in high glucose for 5 days. Total RNA was
isolated and subjected to focused microarray analysis. The table lists
genes differentially regulated by high glucose or FOXO1 siRNA in
high-glucose–treated microvascular endothelial cells. High glucose:
fold change in mRNA level in high-glucose–treated cells versus
standard-glucose–treated cells. High glucose plus FOXO1 siRNA: fold
change in mRNA level of each gene in cells transfected with FOXO1
siRNA plus high glucose versus scrambled siRNA plus high glucose.
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FIG. 6. Comparison of mRNA levels obtained by microarray or real-
time PCR. RMECs were transfected with FOXO1 siRNA or scrambled
siRNA in vitro for 24 h, transferred to standard media (5 mmol/l) or
high-glucose media (25 mmol/l) for 5 days. mRNA levels of CASP3,
ICAM1, VEGF-A, and TNF- were determined by real-ime PCR and
normalized by the level of 18S rRNA in the same sample. Microarray
analysis of the same treatment groups are also shown from values
obtained in Table 2. Data presented is the fold change between each
experimental group and its control (high glucose compared with
standard glucose; FOXO1 siRNA plus HG compared with scrambled
siRNA plus HG. The fold change was converted to log10 scale to
facilitate comparison between different genes. The horizontal solid
line corresponds to 0.23 (log10 equivalent of 1.7 upregulation thresh-
old) and dashed line corresponds to 0.23 (log10 equivalent of 1.7 fold
downregulation threshold). f, microarray high glucose; u, microarray
HG  FOXO1 siRNA; p, quantitative RT-PCR high glucose; , quanti-
tative RT-PCR HG  FOXO1 siRNA.
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